drugset / Trial / NCT00614653
Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to find the highest tolerable dose of capecitabine, erlotinib hydrochloride, and bevacizumab that can be given in combination with radiation to patients with pancreatic cancer.
Timeline
- Start
- 2008-01
- Primary completion
- 2016-07
- Completion
- 2016-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | Capecitabine | Small molecule | 400 mg/m2 | Oral |
| Subject | Erlotinib | Small molecule | 100 mg | Oral |